SCHEMBL2473232

SCHEMBL2473232

COC(=O)C(C)(C)Oc1cc(C)cc(C)c1C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
NPSR1 Q6W5P4 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.34
GLA P06280 1/20 0.34
PKM P14618 1/20 0.34
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FBP1 P09467 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657944 0.83 ALDH1A1 (0.44) ALDH1A1KDM4ENPSR1SMN1; SMN2HTT
SCHEMBL2471788 0.81 NCEH1 (0.39) SMN1; SMN2TP53RAB9AKMT2ALMNA
SCHEMBL21991455 0.80 CYP2C9 (0.49) ALDH1A1SMN1; SMN2HTTTP53RAB9A
SCHEMBL4967835 0.76 CA2 (0.39) ALDH1A1KDM4ENPSR1SMN1; SMN2MEN1
SCHEMBL27096135 0.74 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2TP53RAB9AMAPT
SCHEMBL20689732 0.74 MAPT (0.37) ALDH1A1KDM4ENPSR1SMN1; SMN2HTT
SCHEMBL4173702 0.73 RAB9A (0.38) KDM4ESMN1; SMN2TP53RAB9AMEN1
SCHEMBL2908470 0.73 CNR1 (0.36) ALDH1A1KDM4ENPSR1SMN1; SMN2TP53
SCHEMBL2908107 0.72 FBP1 (0.34) SMN1; SMN2TP53RAB9AKMT2ACNR1
SCHEMBL2908459 0.72 FBP1 (0.42) ALDH1A1SMN1; SMN2TP53RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411052-B1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
US-20070149558-A1 Benzo-fused 5-membered heterocyclic compounds, their production and use OHKAWA SHIGENORI 2007-06-28 US disclosed
US-7208495-B2 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-24 US disclosed
US-20040167171-A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-26 US disclosed
EP-1411052-A1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149558-A1 Benzo-fused 5-membered heterocyclic compounds, their production and use CBR1, DBH, PARK7 ALDH1A1 1019/4885KDM4E 1841/4885NPSR1 928/4885
US-20040167171-A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof CYP8B1, PARK7, OXER1 ALDH1A1 1308/4885KDM4E 2001/4885NPSR1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.